Dedicated to transforming the care of people living with Rare Genetic Disorders of Obesity

We’re focused on the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating weight and hunger.


By targeting the MC4R pathway, we aim to develop therapeutics
for rare genetic disorders of obesity, including:

Proopiomelanocortin
(POMC) Deficiency Obesity
Leptin Receptor (LEPR)
Deficiency Obesity
Bardet-Biedl
Syndrome (BBS)
Alström
Syndrome
POMC and LEPR
Heterozygous Obesity
POMC Epigenetic
Disorders*
Smith-Magenis
Syndrome Obesity
SRC1 Deficiency
Obesity
MC4R Deficiency
Obesity
SH2B1 Deficiency
Obesity

Our news

2020-02-25T08:00:00

Rhythm Pharmaceuticals to Present at Cowen & Co. 40th Annual Health Care Conference

2020-01-06T16:15:00

Rhythm Pharmaceuticals Announces Leadership Transition

2019-12-05T08:00:00

Rhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes